Table 2.

Snapshot analysis of participants after ART treatment

Characteristic	2DR	3DR	P value
HIV-1 RNA (< 50 copies/mL)
Week 12	25 (92.5%)	15 (53.57%)	0.003
Week 24	26 (100%)	20 (83.3%)	0.046
Week48	24 (100%)	24 (100%)	1.000
Change From Baseline in CD4 + count (cells/μL)
Week 12	125.46 ± 149.38	41.2 ± 110.60	0.026
Week 24	209.68 ± 175.88	73.28 ± 162.40	0.020
Week48	204.73 ± 287.32	163.21 ± 121.15	0.805
Change From Baseline in CD4/CD8 ratio
Week 12	0.11 (0.02–0.31)	0.21 (0.11–0.35)	0.058
Week 24	0.15 (0.09–0.36)	0.26 (0.12–0.49)	0.170
Week48	0.13 (0.07–0.39)	0.23 (0.10–0.61)	0.492
Change From Baseline to week 48 in Laboratory Results
ALT	− 3.2 (− 4.55–1.1)	5 (− 0.85–16.35)	0.004
AST	− 4.38 ± 7.64	1.11 ± 10.41	0.217
Cystatin	− 0.1 ± 0.122	− 0.07 ± 0.10	0.439
Urea	− 0.01 ± 1.31	− 0.19 ± 1.13	0.716
eGFR	− 17.27 ± 24.87	2.84 (− 7.1–22.08)	0.052
Hypercholesterolemia	1 (3.70%)	2 (7.14%)	1
Hypertriglyceridemia	3 (11.11%)	5 (17.86%)	0.744
Elevated LDL	1 (3.70%)	0 (0%)	0.49
Elevated HDL	2 (7.41%)	8 (28.57%)	0.092
Elevated creatinine	3 (11.11%)	1 (3.57%)	0.577

Data are presented as mean (SD), medians (interquartile ranges) or No. (%)

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rat; 2DR, two-drug regimen; 3DR, three-drug regimen